A subanalysis of I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction) showed (Table 1) that, in HFpEF, patients with diabetes have more signs of congestion, worse quality of life, higher levels of heart failure biomarkers (N-terminal pro-B-type natriuretic peptide: NT-proBNP), and a poorer prognosis [8]. This evidence concerns the gene NPPB and heart failure.